Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab combination regimens in relapsed or refractory diffuse large B-cell lymphoma
NL-OMON47269Phase 3Withdrawn
- Sponsor
- Pfizer
- Start
- Apr 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of avelumab, rituximab, utomilumab, azacitidine and bendamustine in diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma and non-Hodgkin lymphoma (NHL) (3 arms), sponsored by Pfizer. Primary endpoints: Dose Limiting Toxicity and Objective Response. Planned start Apr 2017; status: withdrawn.
02
Drugs
avelumabrituximabutomilumabazacitidinebendamustine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphomanon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NL-OMON47269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47269.